Clovis Oncology, Inc.CLVS reported two important developments on the regulatory front related to its lead pipeline candidate, rociletinib. Clovis announced that its new drug application for rociletinib has been accepted for priority review by the FDA, which means a
Clovis' Rociletinib under Review in U.S., EU for Lung Cancer
